For Some Biotechs, IRA Remains Intangible – For Now
Some biotech leaders say IRA policies don’t feel consequential yet, though small companies could face impacts from R&D and M&A decision making at big pharmas.

Some biotech leaders say IRA policies don’t feel consequential yet, though small companies could face impacts from R&D and M&A decision making at big pharmas.